CDK4 and neoplasm: For cases with conflicting prognostic signals, relative contraindications or drug interactions, and/or uncertainty around the choice of CDK4/6 inhibitor, we recommend collaborative decision-making through multidisciplinary team reviews, with tumour boards reserved for complex cases.